Bruno Cassinat

28PUBLICATIONS
89CO-AUTHORS
Molecular targetsPredictive and prognostic markersRegenerative medicine (incl. stem cells)Haematological tumoursRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Jul 07, 2025
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.

Nabih Maslah, Nina Kaci, Blandine Roux

|Jun 18, 2025
A molecular signature predicts hematologic evolution in polycythemia vera patients.

Olivier Mansier, Eric Lippert, Lina Benajiba

|Nov 19, 2024
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.

Damien Luque Paz, Nico Gagelmann, Lina Benajiba

|Oct 21, 2024
JAK2V617F-dependent down regulation of SHP-1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF-β.

Céline Aoun, Nabih Maslah, Saravanan Ganesan

|Oct 04, 2024
Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis-insights from a multicenter study.

Yu-Hung Wang, Chao-Hung Wei, Chien-Chin Lin

|May 22, 2024
Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.

Nabih Maslah, Salome Rety, Melina Bonnamy

Pageof 5

Frequent Collaborators

10 joint publications

Jean-Jacques Kiladjian

7 joint publications

Lina Benajiba

7 joint publications

Stephane Giraudier

6 joint publications

Nabih Maslah